PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial
- 15 April 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (8), 2424-2432
- https://doi.org/10.1158/1078-0432.ccr-18-3339
Abstract
Purpose: Endometrioid endometrial cancer is strongly associated with obesity and insulin resistance. Metformin, an insulin sensitizer, reduces endometrial tumor growth in vitro. Presurgical window studies allow rapid in vivo assessment of antitumor activity. Previous window studies found metformin reduced endometrial cancer proliferation but these lacked methodological rigor. PREMIUM measured the anti-proliferative effect of metformin in vivo using a robust window study design. Patients and Methods: A multicenter, double-blind, placebo-controlled trial randomized women with atypical hyperplasia or endometrioid endometrial cancer to receive metformin (850 mg daily for 3 days, and twice daily thereafter) or placebo for 1 to 5 weeks until surgery. The primary outcome was posttreatment IHC expression of Ki-67. Secondary outcomes investigated the effect of metformin on markers of the PI3K–Akt–mTOR and insulin signaling pathways and obesity. Results: Eighty-eight women received metformin (n = 45) or placebo (n = 43) and completed treatment. There was no overall difference in posttreatment Ki-67 between the metformin and placebo arms, in an ANCOVA analysis adjusting for baseline Ki-67 expression (mean difference −0.57%; 95% CI, −7.57%–6.42%; P = 0.87). Metformin did not affect expression of markers of the PI3K–Akt–mTOR or insulin signaling pathways, and did not result in weight loss. Conclusions: Short-term treatment with standard diabetic doses of metformin does not reduce tumor proliferation in women with endometrioid endometrial cancer awaiting hysterectomy. This study does not support a biological effect of metformin in endometrial cancer and casts doubt on its potential application in the primary and adjuvant treatment settings.Keywords
Other Versions
Funding Information
- National Institute for Health Research (NIHR-CS-012-009)
This publication has 36 references indexed in Scilit:
- Effects of metformin on endometrial cancer cell growth in vivo: A preoperative prospective trialCancer, 2014
- Quantitation of Metformin in Human Plasma and Urine by Hydrophilic Interaction Liquid Chromatography and Application to a Pharmacokinetic StudyTherapeutic Drug Monitoring, 2014
- Metformin—mode of action and clinical implications for diabetes and cancerNature Reviews Endocrinology, 2014
- Metformin use and endometrial cancer survivalGynecologic Oncology, 2014
- Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent MannersPLOS ONE, 2013
- Insulin resistance: A significant risk factor of endometrial cancerGynecologic Oncology, 2012
- Metformin Decreases the Dose of Chemotherapy for Prolonging Tumor Remission in Mouse Xenografts Involving Multiple Cancer Cell TypesCancer Research, 2011
- Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006British Journal of Cancer, 2011
- Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancerBreast Cancer Research, 2010
- Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategyGynecologic Oncology, 2010